Recurrent granulosa cell tumor of the retroperitoneum during the COVID-19 Pandemic

Yasmin Abedin; Upasana Madan; Deena Graham; Mira C Hellmann

doi:10.1016/j.gore.2022.100961

Recurrent granulosa cell tumor of the retroperitoneum during the COVID-19 Pandemic

Gynecol Oncol Rep. 2022 Mar 16:40:100961. doi: 10.1016/j.gore.2022.100961. eCollection 2022 Apr.

Authors

Yasmin Abedin¹, Upasana Madan¹, Deena Graham², Mira C Hellmann³

Affiliations

¹ Rutgers New Jersey Medical School Department of Obstetrics & Gynecology and Reproductive Health 185 South Orange Ave, Medical Science Building E-503, Newark, NJ 07103.
² Hackensack University Medical Center Department of Hematology & Oncology, Division of Gynecologic Medical Oncology 92 2nd Street, Hackensack, NJ 07601.
³ Hackensack University Medical Center Department of Obstetrics and Gynecology, Division of Gynecologic Oncology 92 2nd Street, Hackensack, NJ 07601.

Abstract

Extraovarian granulosa cell tumors are rare with very few cases of isolated retroperitoneal granulosa cell tumors reported in the literature. Granulosa cell tumors are notorious for late recurrences and patients should have long term oncologic follow up. We describe a case of recurrent granulosa cell tumor of the retroperitoneum that originally presented as a renal mass, which has not been described before in the literature. Her management was delayed in part due to the COVID-19 Pandemic. Oncologists must be vigilant regarding the consequences of postponed care during this difficult time.

Keywords: COVID-19 Pandemic; Delays in care; Extraovarian; Granulosa cell tumors; Retroperitoneal.

Publication types

Case Reports